Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ABP
ABP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ABP News
Fastly Reports Strong Quarterly Earnings Exceeding Expectations
Feb 12 2026
Benzinga
U.S. Stocks Mixed in Morning Trading
Feb 10 2026
Benzinga
Credo Technology Raises Revenue Guidance Significantly
Feb 10 2026
Benzinga
Abpro Submits IND for ABP-102/CT-P72, Initiating Phase 1 Clinical Trial
Dec 15 2025
Globenewswire
Abpro Submits IND Application for ABP-102/CT-P72, Targeting HER2-Positive Cancers
Dec 15 2025
Newsfilter
Abpro Holdings Secures Nasdaq Compliance Extension Until 2026
Dec 09 2025
Globenewswire
Stock Splits Scheduled for This Week (November 3 to November 7) – Keep Your Investments Active
Nov 02 2025
TipRanks
Sitryx Names Adam Mostafa as CFO
Sep 08 2025
Newsfilter
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 19 2025
Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
May 16 2025
Benzinga
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
May 15 2025
Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
May 14 2025
Benzinga
Why Amplify Energy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Apr 28 2025
Benzinga
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Apr 27 2025
Newsfilter
Abpro and Celltrion Reveal Promising Preclinical Data for Bispecific T-Cell Engager ABP-102/CT-P72 Targeting HER2-Positive Cancers
Apr 01 2025
NASDAQ.COM
Abpro Holdings, Inc. Announces Departure of CEO Ian Chan and Commitment to Future Leadership and Initiatives
Mar 10 2025
NASDAQ.COM
Show More News
